Moderna stock surges as melanoma vaccine trial shows "landmark moment"
Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.
Moderna's stock skyrocketed more than 145% on Wednesday as the pharmaceutical giant unveiled promising results from a melanoma vaccine trial. The experimental mRNA treatment, developed in collaboration with Merck, demonstrated remarkable efficacy in preventing the deadly skin cancer from returning or spreading in high-risk patients.
Shares of Moderna shot up $91.52, or 145%, to $154.48 in early trading, while Merck's shares climbed $14.35, or 10.6%, to $149.52. The groundbreaking study, led by Professor Georgina Long, a melanoma oncology expert at the University of Sydney, showcased the vaccine's potential to significantly reduce the risk of recurrence and death in melanoma patients.
With over 234,680 new cases of melanoma expected in the U.S. in 2026, this landmark achievement marks a pivotal moment in cancer research and could usher in a new era of personalized, adjuvant melanoma treatments.
Written by urgent.news from CBS News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
